Published in Elder Law Weekly, August 3rd, 2005
The grant will fund the clinical development of the company's lead compound, ATL-146e, to prevent reperfusion injury. The amount of the award is approximately $2.0 million, and will be used to support the completion of phase I and phase II clinical trials to develop a drug to prevent cardiac reperfusion injury.
"The primary goal of this project is to expedite clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.